Tafluprost

CAS 209860-87-7 6 current recordsSmall Molecule

Who holds supplier records for Tafluprost? 6 organisations hold a current record for Tafluprost: an active US FDA Type II Drug Master File. Recorded organisation countries for current records: Taiwan (2), Japan (1), Czechia (1), India (1) and 1 other country (1).

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Tafluprost: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/tafluprost

Reading the evidence

  • 6 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • 3 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

  • US product patents listed

    The latest patent listed in the FDA Orange Book for an approved product containing Tafluprost expires 28 May 2029. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.

Current records (6)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Tafluprost. Country is the organisation's recorded country, not necessarily the manufacturing site.

Need Tafluprost sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

US product patents and exclusivity

The FDA Orange Book lists patents and exclusivities for specific approved products (4 listed products contain Tafluprost). The latest listed patent expires 28 May 2029. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.

Overview

Tafluprost is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL1963683).

Chemical identity

IUPAC name
propan-2-yl (Z)-7-[(1R,2R,3R,5S)-2-[(E)-3,3-difluoro-4-phenoxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate
Canonical SMILES
CC(C)OC(=O)CCC/C=C\C[C@H]1[C@H](C[C@H]([C@@H]1/C=C/C(COC2=CC=CC=C2)(F)F)O)O
InChIKey
WSNODXPBBALQOF-VEJSHDCNSA-N
Synonyms
AFP-168, MK-2452, Saflutan, Tafluprost, Zioptan, Taflotan, CHEBI:66899, MK2452, tafluprostum, tafluprost opthalmic, Tafluprost Ophthalmic, RefChem:57842

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
Prostaglandin Analog
Mechanism of action
Prostaglandin Receptor Agonists
Physiologic effect
Increased Prostaglandin Activity
Chemical structure
Prostaglandins

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Tafluprost?

6 organisations hold an active US FDA Type II Drug Master File or a CEP for Tafluprost: AGC INC (Japan), CAYMAN PHARMA SRO (Czechia), CHIROGATE INTERNATIONAL INC (Taiwan), EVERLIGHT CHEMICAL INDUSTRIAL CORP (Taiwan), MSN Laboratories Private Limited (India) and Zhejiang Ausun Pharmaceutical Co., Ltd. (China). A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Tafluprost Drug Master Files are active?

AGC INC (DMF 24400), CAYMAN PHARMA SRO (DMF 35765), CHIROGATE INTERNATIONAL INC (DMF 33632), EVERLIGHT CHEMICAL INDUSTRIAL CORP (DMF 29564), MSN Laboratories Private Limited (DMF 29206) and Zhejiang Ausun Pharmaceutical Co., Ltd. (DMF 39505). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

Does the FDA Orange Book list patents for products containing Tafluprost?

Yes. The latest patent listed for an approved US product containing Tafluprost expires 28 May 2029, across 4 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.

How do I qualify a Tafluprost supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Tafluprost?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.